Questions stringlengths 22 157 ⌀ | Answers stringlengths 95 1.52k ⌀ | text stringlengths 32 1.68k |
|---|---|---|
How is breast cancer treated? | Surgery is considered primary treatment for early-stage breast cancer; many patients are cured with surgery alone.Adjuvant treatment of breast cancer is designed to treat micrometastatic disease (ie, breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis) | <s>[INST] How is breast cancer treated? [/INST] Surgery is considered primary treatment for early-stage breast cancer; many patients are cured with surgery alone.Adjuvant treatment of breast cancer is designed to treat micrometastatic disease (ie, breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis) </s> |
How is invasive breast cancer treated? | There are many treatments for invasive breast cancer. They include:
1) Surgery. A lumpectomy is a surgical procedure in which a surgeon removes the cancer and a small area of healthy tissue around it. A mastectomy may be performed after chemotherapy. This procedure removes all of your breast.
2) Chemotherapy. This drug treatment may be done before surgery to shrink the tumor and make the cancer operable. It’s also sometimes given after surgery to try to prevent the cancer from coming back.
3) Radiation. Often, radiation treatments are given after chemotherapy and surgery to prevent the cancer from coming back.
4) Hormone therapy. Certain medications may be given if the cancer cells have hormone receptors.
5) Targeted therapy. If the cancer cells have the gene HER2, you may be given drug treatments specifically for that.
To know more about invasive breast cancer visit: https://www.webmd.com/breast-cancer/invasive-breast-cancer | <s>[INST] How is invasive breast cancer treated? [/INST] There are many treatments for invasive breast cancer. They include:
1) Surgery. A lumpectomy is a surgical procedure in which a surgeon removes the cancer and a small area of healthy tissue around it. A mastectomy may be performed after chemotherapy. This procedure removes all of your breast.
2) Chemotherapy. This drug treatment may be done before surgery to shrink the tumor and make the cancer operable. It’s also sometimes given after surgery to try to prevent the cancer from coming back.
3) Radiation. Often, radiation treatments are given after chemotherapy and surgery to prevent the cancer from coming back.
4) Hormone therapy. Certain medications may be given if the cancer cells have hormone receptors.
5) Targeted therapy. If the cancer cells have the gene HER2, you may be given drug treatments specifically for that.
To know more about invasive breast cancer visit: https://www.webmd.com/breast-cancer/invasive-breast-cancer </s> |
What are the guidelines for breast-conserving surgery with whole-breast irradiation (WBI) in stages I and II invasive breast cancer? | The following are guidelines, released by the Society of Surgical Oncology and the American Society for Radiation Oncology:
1) Positive margins are associated with at least a 2-fold increase in ipsilateral breast tumor recurrence (IBTR)
2) Negative margins optimize IBTR; this risk is not significantly lowered by wider margin widths
3) IBTR rates are reduced with the use of systemic therapy; in patients who do not receive adjuvant systemic therapy, margins wider than no ink on tumor are not needed
4) Biologic subtypes do not indicate the need for margins wider than no ink on tumor
5) Margin width should not determine the choice of WBI delivery technique, fractionation, and boost dose.
6) Wider negative margins than no ink on tumor are not indicated for patients with invasive lobular cancer; classic lobular carcinoma in situ (LCIS) at the margin is not an indication for reexcision; the significance of pleomorphic LCIS at the margin is not clear
7) Young age is associated with an increased risk for IBTR after breast-conserving therapy, an increased risk for local relapse on the chest wall after mastectomy, and adverse biologic and pathologic features; an increased margin width does not nullify the increased risk for IBTR in young patients
8) An extensive intraductal component (EIC) identifies patients who may have a large residual ductal carcinoma in situ (DCIS) burden after lumpectomy; when margins are negative, there is no evidence of an association between an increased risk for IBTR and EIC | <s>[INST] What are the guidelines for breast-conserving surgery with whole-breast irradiation (WBI) in stages I and II invasive breast cancer? [/INST] The following are guidelines, released by the Society of Surgical Oncology and the American Society for Radiation Oncology:
1) Positive margins are associated with at least a 2-fold increase in ipsilateral breast tumor recurrence (IBTR)
2) Negative margins optimize IBTR; this risk is not significantly lowered by wider margin widths
3) IBTR rates are reduced with the use of systemic therapy; in patients who do not receive adjuvant systemic therapy, margins wider than no ink on tumor are not needed
4) Biologic subtypes do not indicate the need for margins wider than no ink on tumor
5) Margin width should not determine the choice of WBI delivery technique, fractionation, and boost dose.
6) Wider negative margins than no ink on tumor are not indicated for patients with invasive lobular cancer; classic lobular carcinoma in situ (LCIS) at the margin is not an indication for reexcision; the significance of pleomorphic LCIS at the margin is not clear
7) Young age is associated with an increased risk for IBTR after breast-conserving therapy, an increased risk for local relapse on the chest wall after mastectomy, and adverse biologic and pathologic features; an increased margin width does not nullify the increased risk for IBTR in young patients
8) An extensive intraductal component (EIC) identifies patients who may have a large residual ductal carcinoma in situ (DCIS) burden after lumpectomy; when margins are negative, there is no evidence of an association between an increased risk for IBTR and EIC </s> |
What is the role of post lumpectomy radiation therapy in the treatment of breast cancer? | > The purpose of radiation therapy after breast-conserving surgery is to eradicate local subclinical residual disease while reducing local recurrence rates by approximately 75%. On the basis of results from several randomized controlled studies, irradiation of the intact breast is considered standard of care, even in the lowest-risk disease with the most favorable prognostic features.
> There are 2 general approaches used to deliver radiation therapy: conventional external-beam radiotherapy (EBRT) and partial-breast irradiation (PBI). Whole-breast radiotherapy (WBRT) consists of EBRT delivered to the breast at a dose of 50-55 Gy over 5-6 weeks. This is often followed by a boost dose specifically directed to the area in the breast where the tumor was removed. | <s>[INST] What is the role of post lumpectomy radiation therapy in the treatment of breast cancer? [/INST] > The purpose of radiation therapy after breast-conserving surgery is to eradicate local subclinical residual disease while reducing local recurrence rates by approximately 75%. On the basis of results from several randomized controlled studies, irradiation of the intact breast is considered standard of care, even in the lowest-risk disease with the most favorable prognostic features.
> There are 2 general approaches used to deliver radiation therapy: conventional external-beam radiotherapy (EBRT) and partial-breast irradiation (PBI). Whole-breast radiotherapy (WBRT) consists of EBRT delivered to the breast at a dose of 50-55 Gy over 5-6 weeks. This is often followed by a boost dose specifically directed to the area in the breast where the tumor was removed. </s> |
What are the ASBrS selection criteria for treatment of breast cancer with accelerated partial breast irradiation (PBI)? | The American Society of Breast Surgeons (ASBrS) recommends the following selection criteria when patients are being considered for treatment with accelerated PBI :
1) Age ≥45 years for all tumor types
2) All invasive subtypes or DCIS
3) Total tumor size (invasive and DCIS) ≤ 3 cm
4) T stage Tis, T1, T2 (≤ 3 cm)
5) Margins; No tumor on ink for invasive tumors or tumors involved with DCIS; ≥2 mm for DCIS
6) Node negative
7) Multifocal acceptable if total span of tumors is ≤3 cm
8) Estrogen receptor positive or negative
9) Focal lymphovascular invasion
10) No genetic mutations | <s>[INST] What are the ASBrS selection criteria for treatment of breast cancer with accelerated partial breast irradiation (PBI)? [/INST] The American Society of Breast Surgeons (ASBrS) recommends the following selection criteria when patients are being considered for treatment with accelerated PBI :
1) Age ≥45 years for all tumor types
2) All invasive subtypes or DCIS
3) Total tumor size (invasive and DCIS) ≤ 3 cm
4) T stage Tis, T1, T2 (≤ 3 cm)
5) Margins; No tumor on ink for invasive tumors or tumors involved with DCIS; ≥2 mm for DCIS
6) Node negative
7) Multifocal acceptable if total span of tumors is ≤3 cm
8) Estrogen receptor positive or negative
9) Focal lymphovascular invasion
10) No genetic mutations </s> |
What are the potential complications of partial breast irradiation (PBI) in the treatment of breast cancer? | Potential complications of PBI are catheter placement followed by removal secondary to any of the following:
1) Inadequate skin spacing
2) Infection
3) Seroma
4) Fibrosis
5) Chronic pain
6) Disease recurrence | <s>[INST] What are the potential complications of partial breast irradiation (PBI) in the treatment of breast cancer? [/INST] Potential complications of PBI are catheter placement followed by removal secondary to any of the following:
1) Inadequate skin spacing
2) Infection
3) Seroma
4) Fibrosis
5) Chronic pain
6) Disease recurrence </s> |
What is the efficacy of external-beam radiotherapy (EBRT) in the treatment of breast cancer? | The most common type of radiation therapy for breast cancer, EBRT is generally given after other treatments are complete.
In EBRT, a beam of radiation, a high-energy X-ray, is focused on the spot where the cancer was removed. If a lumpectomy was performed, a patient may receive EBRT to the entire breast, a technique called whole-breast radiation. EBRT may also be delivered to nearby lymph nodes. Some advantages of EBRT for breast cancer patients may include:
1) It is fast, painless and performed as an outpatient procedure.
2) Unlike chemotherapy, which circulates throughout the body, EBRT is targeted to the treatment area.
3) At no point during radiation therapy is a patient radioactive, and there’s no risk of radioactivity to your friends and family. | <s>[INST] What is the efficacy of external-beam radiotherapy (EBRT) in the treatment of breast cancer? [/INST] The most common type of radiation therapy for breast cancer, EBRT is generally given after other treatments are complete.
In EBRT, a beam of radiation, a high-energy X-ray, is focused on the spot where the cancer was removed. If a lumpectomy was performed, a patient may receive EBRT to the entire breast, a technique called whole-breast radiation. EBRT may also be delivered to nearby lymph nodes. Some advantages of EBRT for breast cancer patients may include:
1) It is fast, painless and performed as an outpatient procedure.
2) Unlike chemotherapy, which circulates throughout the body, EBRT is targeted to the treatment area.
3) At no point during radiation therapy is a patient radioactive, and there’s no risk of radioactivity to your friends and family. </s> |
What is the role of single-dose radiotherapy in the treatment of breast cancer? | According to 2 major studies, single-dose radiotherapy delivered during or soon after surgery for breast cancer is a viable alternative to conventional EBRT in selected patients who are at low risk for local recurrence. | <s>[INST] What is the role of single-dose radiotherapy in the treatment of breast cancer? [/INST] According to 2 major studies, single-dose radiotherapy delivered during or soon after surgery for breast cancer is a viable alternative to conventional EBRT in selected patients who are at low risk for local recurrence. </s> |
What are the ASCO criteria for postmastectomy radiation therapy in the treatment of breast cancer? | Clinical practice guidelines developed by the American Society of Clinical Oncology (ASCO), along with several prospective, randomized clinical trials, recommend that postmastectomy radiation therapy be performed according to the following criteria :
1) Positive postmastectomy margins
2) Primary tumors >5 cm
3) Involvement of ≥4 lymph nodes | <s>[INST] What are the ASCO criteria for postmastectomy radiation therapy in the treatment of breast cancer? [/INST] Clinical practice guidelines developed by the American Society of Clinical Oncology (ASCO), along with several prospective, randomized clinical trials, recommend that postmastectomy radiation therapy be performed according to the following criteria :
1) Positive postmastectomy margins
2) Primary tumors >5 cm
3) Involvement of ≥4 lymph nodes </s> |
What is the efficacy of radiation therapy for the treatment of invasive breast cancer? | If early-stage breast cancer hasn’t spread, radiation therapy after a lumpectomy significantly reduces the risk of cancer coming back by approximately 50%. Studies show that a lumpectomy followed by radiation therapy is as effective as a mastectomy without radiation therapy. | <s>[INST] What is the efficacy of radiation therapy for the treatment of invasive breast cancer? [/INST] If early-stage breast cancer hasn’t spread, radiation therapy after a lumpectomy significantly reduces the risk of cancer coming back by approximately 50%. Studies show that a lumpectomy followed by radiation therapy is as effective as a mastectomy without radiation therapy. </s> |
What is the role of systemic adjuvant therapy in the treatment of breast cancer? | Adjuvant treatment of breast cancer is designed to treat micrometastatic disease (ie, breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer-related morbidity and mortality. Depending on the model of risk reduction, adjuvant therapy has been estimated to be responsible for 35-72% of the reduction in mortality. | <s>[INST] What is the role of systemic adjuvant therapy in the treatment of breast cancer? [/INST] Adjuvant treatment of breast cancer is designed to treat micrometastatic disease (ie, breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer-related morbidity and mortality. Depending on the model of risk reduction, adjuvant therapy has been estimated to be responsible for 35-72% of the reduction in mortality. </s> |
How is DCIS breast cancer treated? | Currently, the standard treatment of DCIS is surgical resection with or without radiation. Adjuvant radiation and hormonal therapies are often reserved for younger women, patients undergoing lumpectomy, or those with the comedo subtype. Local treatment for DCIS usually involves breast-conserving therapy (BCT), which consists of lumpectomy (also called wide excision or partial mastectomy) followed in most cases by adjuvant radiation therapy (RT). Alternatively, mastectomy may be considered | <s>[INST] How is DCIS breast cancer treated? [/INST] Currently, the standard treatment of DCIS is surgical resection with or without radiation. Adjuvant radiation and hormonal therapies are often reserved for younger women, patients undergoing lumpectomy, or those with the comedo subtype. Local treatment for DCIS usually involves breast-conserving therapy (BCT), which consists of lumpectomy (also called wide excision or partial mastectomy) followed in most cases by adjuvant radiation therapy (RT). Alternatively, mastectomy may be considered </s> |
What is the role of WBRT in the treatment of DCIS breast cancer? | In DCIS, WBRT is delivered over 5-6 weeks after surgery, reducing the local recurrence rate by approximately 60%. Roughly 50% of local recurrences are invasive breast cancer. Meta-analyses of randomized controlled trials have demonstrated slightly higher rates of contralateral breast cancer with radiation therapy than with observation (3.85% vs 2.5%) after surgery for DCIS. Studies comparing accelerated PBI given over 5 days to standard WBRT are currently under way. | <s>[INST] What is the role of WBRT in the treatment of DCIS breast cancer? [/INST] In DCIS, WBRT is delivered over 5-6 weeks after surgery, reducing the local recurrence rate by approximately 60%. Roughly 50% of local recurrences are invasive breast cancer. Meta-analyses of randomized controlled trials have demonstrated slightly higher rates of contralateral breast cancer with radiation therapy than with observation (3.85% vs 2.5%) after surgery for DCIS. Studies comparing accelerated PBI given over 5 days to standard WBRT are currently under way. </s> |
What is the role of tamoxifen in the treatment of DCIS breast cancer? | Tamoxifen is the only hormonal therapy currently approved for adjuvant therapy in patients treated with breast-conserving surgery and radiation for DCIS. A retrospective study found that patients with ER-positive DCIS who were treated with tamoxifen showed significant decreases in subsequent breast cancer at 10 years. Adjuvant tamoxifen also reduces the risk of contralateral breast cancer. | <s>[INST] What is the role of tamoxifen in the treatment of DCIS breast cancer? [/INST] Tamoxifen is the only hormonal therapy currently approved for adjuvant therapy in patients treated with breast-conserving surgery and radiation for DCIS. A retrospective study found that patients with ER-positive DCIS who were treated with tamoxifen showed significant decreases in subsequent breast cancer at 10 years. Adjuvant tamoxifen also reduces the risk of contralateral breast cancer. </s> |
How is LCIS breast cancer treated? | Overall, treatment options for lobular carcinoma in situ (LCIS) include observation and close follow-up care with or without tamoxifen and bilateral mastectomy with or without reconstruction. There is no evidence of therapeutic benefit from local excision, axillary dissection, radiotherapy, or chemotherapy. LCIS in the breast of a woman with ductal or lobular cancer does not require further immediate surgery on the opposite breast. Mirror biopsy of the contralateral breast, once advocated for treatment of LCIS, is now mainly of historic interest. | <s>[INST] How is LCIS breast cancer treated? [/INST] Overall, treatment options for lobular carcinoma in situ (LCIS) include observation and close follow-up care with or without tamoxifen and bilateral mastectomy with or without reconstruction. There is no evidence of therapeutic benefit from local excision, axillary dissection, radiotherapy, or chemotherapy. LCIS in the breast of a woman with ductal or lobular cancer does not require further immediate surgery on the opposite breast. Mirror biopsy of the contralateral breast, once advocated for treatment of LCIS, is now mainly of historic interest. </s> |
How is locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) treated? | LABC is often treated with a combination of chemotherapy, surgery, and radiation therapy.
NOTE: Chemotherapy is not given every day but instead is given in cycles. A cycle of chemotherapy refers to the time it takes to give the chemotherapy and then allow the body to recover. A cycle of chemotherapy typically ranges from two to four weeks.
The treatment of inflammatory breast cancer is similar to that of other types of locally advanced breast cancer (LABC). Treatment usually includes neoadjuvant chemotherapy, surgery, and radiation therapy. As with other forms of LABC, two types of chemotherapy agents (anthracyclines and a taxane) are usually used. Once the diagnosis of inflammatory breast cancer (IBC) is established, it is important to proceed rapidly to treatment, as this is considered a rapidly spreading cancer.
There are some important differences in the treatment of IBC compared with LABC. In IBC, a mastectomy is usually recommended, even if the cancer responded well to neoadjuvant chemotherapy. After mastectomy, radiation therapy to the chest wall and lymph nodes is strongly recommended. Immediate reconstruction is NOT recommended in IBC.
| <s>[INST] How is locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) treated? [/INST] LABC is often treated with a combination of chemotherapy, surgery, and radiation therapy.
NOTE: Chemotherapy is not given every day but instead is given in cycles. A cycle of chemotherapy refers to the time it takes to give the chemotherapy and then allow the body to recover. A cycle of chemotherapy typically ranges from two to four weeks.
The treatment of inflammatory breast cancer is similar to that of other types of locally advanced breast cancer (LABC). Treatment usually includes neoadjuvant chemotherapy, surgery, and radiation therapy. As with other forms of LABC, two types of chemotherapy agents (anthracyclines and a taxane) are usually used. Once the diagnosis of inflammatory breast cancer (IBC) is established, it is important to proceed rapidly to treatment, as this is considered a rapidly spreading cancer.
There are some important differences in the treatment of IBC compared with LABC. In IBC, a mastectomy is usually recommended, even if the cancer responded well to neoadjuvant chemotherapy. After mastectomy, radiation therapy to the chest wall and lymph nodes is strongly recommended. Immediate reconstruction is NOT recommended in IBC.
</s> |
What is the prognosis of locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) following treatment? | Overall, the prognosis is better for women with T3N0 (stage IIB) and T3N1 (stage IIIA) breast cancer than it is for those with classically defined LABC (IIIB, IIIC) or IBC (IIIB, T4d). Disease-free survival (DFS) and overall survival are typically better for stage IIB and IIIA patients; however, the likelihood of achieving a pathologic complete response (pCR) from neoadjuvant treatment, a well-recognized surrogate for long-term outcome, is inversely related to tumor size. Thus, the relative proportions of patients in each category are important. | <s>[INST] What is the prognosis of locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC) following treatment? [/INST] Overall, the prognosis is better for women with T3N0 (stage IIB) and T3N1 (stage IIIA) breast cancer than it is for those with classically defined LABC (IIIB, IIIC) or IBC (IIIB, T4d). Disease-free survival (DFS) and overall survival are typically better for stage IIB and IIIA patients; however, the likelihood of achieving a pathologic complete response (pCR) from neoadjuvant treatment, a well-recognized surrogate for long-term outcome, is inversely related to tumor size. Thus, the relative proportions of patients in each category are important. </s> |
What is inflammatory breast cancer (IBC)? | IBC is a clinical diagnosis that implies presentation with the cardinal signs of inflammation (calor [warmth], rubor [redness], tumor [mass]) involving the breast, although the warmth may be subtle and the mass may not be appreciated as something discrete. Indeed, even when a localized mass is apparent in IBC, the true extent of the disease (as shown by performing skin biopsies from the surrounding normal-appearing skin) is usually greater than is apparent on physical examination. | <s>[INST] What is inflammatory breast cancer (IBC)? [/INST] IBC is a clinical diagnosis that implies presentation with the cardinal signs of inflammation (calor [warmth], rubor [redness], tumor [mass]) involving the breast, although the warmth may be subtle and the mass may not be appreciated as something discrete. Indeed, even when a localized mass is apparent in IBC, the true extent of the disease (as shown by performing skin biopsies from the surrounding normal-appearing skin) is usually greater than is apparent on physical examination. </s> |
What is locally advanced breast cancer (LABC)? | LABC is more common in the US than IBC is; by the definition used here, it may account for 10-15% of patients (this drops to about 5% if one uses the older, stricter definition that includes inoperability). Epidemiologically, LABC is associated with lower socioeconomic class and, probably for that reason, with black race in the United States.
LABC encompasses both relatively indolent neglected tumors and those that have grown rapidly as a result of their inherent biology. In most case series, LABC has a better long-term outcome than IBC does, even when only inoperable cases are considered. | <s>[INST] What is locally advanced breast cancer (LABC)? [/INST] LABC is more common in the US than IBC is; by the definition used here, it may account for 10-15% of patients (this drops to about 5% if one uses the older, stricter definition that includes inoperability). Epidemiologically, LABC is associated with lower socioeconomic class and, probably for that reason, with black race in the United States.
LABC encompasses both relatively indolent neglected tumors and those that have grown rapidly as a result of their inherent biology. In most case series, LABC has a better long-term outcome than IBC does, even when only inoperable cases are considered. </s> |
How are lymph nodes evaluated in locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC)? | Patients with LABC or IBC with clinically positive nodes should undergo a core biopsy before initiating chemotherapy. Those with clinically negative nodes may undergo sentinel lymph node biopsy before they start treatment, or else sentinel node determination may be delayed until after treatment is completed. In general, the best single test for evaluating the status of measurable tumor is ultrasonography (preferably done by the same operator). The mass often appears larger on physical examination than on ultrasonography, which can more effectively discriminate hypoechoic masses from surrounding stroma or hematoma. In IBC, magnetic resonance imaging (MRI) may be an important adjunct to response assessment. The role of positron emission tomography (PET) in routine assessment of response must be determined on a case-by-case basis. | <s>[INST] How are lymph nodes evaluated in locally advanced breast cancer (LABC) and inflammatory breast cancer (IBC)? [/INST] Patients with LABC or IBC with clinically positive nodes should undergo a core biopsy before initiating chemotherapy. Those with clinically negative nodes may undergo sentinel lymph node biopsy before they start treatment, or else sentinel node determination may be delayed until after treatment is completed. In general, the best single test for evaluating the status of measurable tumor is ultrasonography (preferably done by the same operator). The mass often appears larger on physical examination than on ultrasonography, which can more effectively discriminate hypoechoic masses from surrounding stroma or hematoma. In IBC, magnetic resonance imaging (MRI) may be an important adjunct to response assessment. The role of positron emission tomography (PET) in routine assessment of response must be determined on a case-by-case basis. </s> |
What are the systemic treatments for metastatic breast cancer? | Although treatments for metastatic breast cancer continue to improve, there remains no cure once distant metastases develop.
Furthermore, although occasional patients with metastatic breast cancer benefit from surgical resection for an isolated recurrence and many require radiation therapy for palliation at a specific site (or definitive treatment of brain metastasis), in general, recurrent or metastatic breast cancer must be approached systemically so that the therapeutic effect reaches all sites of disease. There are two main interventions: hormone therapy and chemotherapy. | <s>[INST] What are the systemic treatments for metastatic breast cancer? [/INST] Although treatments for metastatic breast cancer continue to improve, there remains no cure once distant metastases develop.
Furthermore, although occasional patients with metastatic breast cancer benefit from surgical resection for an isolated recurrence and many require radiation therapy for palliation at a specific site (or definitive treatment of brain metastasis), in general, recurrent or metastatic breast cancer must be approached systemically so that the therapeutic effect reaches all sites of disease. There are two main interventions: hormone therapy and chemotherapy. </s> |
What is the role of hormone therapy in the treatment of metastatic breast cancer? | Hormone therapy (also called hormonal therapy, hormone treatment, or endocrine therapy) slows or stops the growth of hormone-sensitive tumors by blocking the body’s ability to produce hormones or by interfering with effects of hormones on breast cancer cells. Tumors that are hormone insensitive do not have hormone receptors and do not respond to hormone therapy. | <s>[INST] What is the role of hormone therapy in the treatment of metastatic breast cancer? [/INST] Hormone therapy (also called hormonal therapy, hormone treatment, or endocrine therapy) slows or stops the growth of hormone-sensitive tumors by blocking the body’s ability to produce hormones or by interfering with effects of hormones on breast cancer cells. Tumors that are hormone insensitive do not have hormone receptors and do not respond to hormone therapy. </s> |
What is the role of chemotherapy in the treatment of metastatic breast cancer? | Chemotherapy is used as a treatment for most people who have metastatic breast cancer. Whether it is used first-line or not depends on your receptor status, previous treatments, and other factors Chemotherapy can work very well for metastatic breast cancer, although tumors almost always become resistant to any given drug or combination of drugs over time. It is not uncommon for people to undergo at least three different chemotherapy regimens during treatment.. Chemotherapy for metastatic breast cancer is not expected to cure the disease, but instead to control the disease for as long as possible. Chemotherapy for metastatic breast cancer, however, is used with different goals.
These goals are:
To extend your life
To improve your quality of life
To ease your symptoms | <s>[INST] What is the role of chemotherapy in the treatment of metastatic breast cancer? [/INST] Chemotherapy is used as a treatment for most people who have metastatic breast cancer. Whether it is used first-line or not depends on your receptor status, previous treatments, and other factors Chemotherapy can work very well for metastatic breast cancer, although tumors almost always become resistant to any given drug or combination of drugs over time. It is not uncommon for people to undergo at least three different chemotherapy regimens during treatment.. Chemotherapy for metastatic breast cancer is not expected to cure the disease, but instead to control the disease for as long as possible. Chemotherapy for metastatic breast cancer, however, is used with different goals.
These goals are:
To extend your life
To improve your quality of life
To ease your symptoms </s> |
Which chemotherapy agents are used in the treatment of metastatic breast cancer? | Check out the agents: https://www.medscape.com/answers/1947145-155366/what-is-the-role-of-chemotherapy-in-the-treatment-of-metastatic-breast-cancer | <s>[INST] Which chemotherapy agents are used in the treatment of metastatic breast cancer? [/INST] Check out the agents: https://www.medscape.com/answers/1947145-155366/what-is-the-role-of-chemotherapy-in-the-treatment-of-metastatic-breast-cancer </s> |
What is the role of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of metastatic breast cancer? | PARP inhibitors are a type of targeted (biological) therapy.
PARP stands for poly-ADP ribose polymerase. It’s a protein that helps cells repair themselves if they become damaged. PARP inhibitors stop the PARP from repairing cancer cells.
Two inherited altered genes that increase the risk of breast cancer developing are called BRCA1 and BRCA2. Cancer cells with faulty BRCA genes are already less able to repair themselves if they become damaged. Adding PARP inhibitors blocks another way cancer cells can repair themselves and causes them to become too damaged to survive. | <s>[INST] What is the role of poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of metastatic breast cancer? [/INST] PARP inhibitors are a type of targeted (biological) therapy.
PARP stands for poly-ADP ribose polymerase. It’s a protein that helps cells repair themselves if they become damaged. PARP inhibitors stop the PARP from repairing cancer cells.
Two inherited altered genes that increase the risk of breast cancer developing are called BRCA1 and BRCA2. Cancer cells with faulty BRCA genes are already less able to repair themselves if they become damaged. Adding PARP inhibitors blocks another way cancer cells can repair themselves and causes them to become too damaged to survive. </s> |
What is the efficacy of combination therapy in the treatment of triple-negative breast cancer? | Unresectable metastatic triple-negative breast cancer (ie, estrogen receptor–negative, progesterone receptor–negative, and HER2 receptor–negative) is aggressive and carries a poor prognosis. However, combination therapy with the programmed cell death ligand–1 (PDL1) inhibitor atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel has been shown to prolong PFS in these patients. In 2019, FDA approved atezolizumab in combination with nab-paclitaxel for triple-negative breast cancer. The combination therapy attacked the tumor on two fronts. On one side, the chemotherapy drug cyclophosphamide eliminated tumor cells, while on the other front, another drug inhibited tumor-associated cells called macrophages, which block the body’s immune response against the tumor. This two-front strategy effectively treated several highly aggressive TNBC primary tumors and metastasis | <s>[INST] What is the efficacy of combination therapy in the treatment of triple-negative breast cancer? [/INST] Unresectable metastatic triple-negative breast cancer (ie, estrogen receptor–negative, progesterone receptor–negative, and HER2 receptor–negative) is aggressive and carries a poor prognosis. However, combination therapy with the programmed cell death ligand–1 (PDL1) inhibitor atezolizumab plus nanoparticle albumin-bound (nab)–paclitaxel has been shown to prolong PFS in these patients. In 2019, FDA approved atezolizumab in combination with nab-paclitaxel for triple-negative breast cancer. The combination therapy attacked the tumor on two fronts. On one side, the chemotherapy drug cyclophosphamide eliminated tumor cells, while on the other front, another drug inhibited tumor-associated cells called macrophages, which block the body’s immune response against the tumor. This two-front strategy effectively treated several highly aggressive TNBC primary tumors and metastasis </s> |
What is the role of antiangiogenic therapy in the treatment of metastatic breast cancer? | null | <s>[INST] What is the role of antiangiogenic therapy in the treatment of metastatic breast cancer? [/INST] None </s> |
What is the role of surgery for the treatment of metastatic breast cancer? | There is increasing interest in the role of surgical intervention for the intact primary tumor of these metastatic breast cancer patients. Several single-institution cohort and retrospective studies have concluded that surgical resection of the intact primary tumor may provide a survival advantage.
It is still unknown whether a selection bias affects the findings of a survival advantage in favor of surgery. However, the dogmatic belief that one should never operate in the setting of metastatic disease has certainly been dispelled in favor of critical evaluation of whether surgically achieved local control can lead to improved survival as a part of multimodal treatment. An ongoing prospective randomized clinical trial, E2108, is addressing the role of surgery for the primary tumor in metastatic setting. | <s>[INST] What is the role of surgery for the treatment of metastatic breast cancer? [/INST] There is increasing interest in the role of surgical intervention for the intact primary tumor of these metastatic breast cancer patients. Several single-institution cohort and retrospective studies have concluded that surgical resection of the intact primary tumor may provide a survival advantage.
It is still unknown whether a selection bias affects the findings of a survival advantage in favor of surgery. However, the dogmatic belief that one should never operate in the setting of metastatic disease has certainly been dispelled in favor of critical evaluation of whether surgically achieved local control can lead to improved survival as a part of multimodal treatment. An ongoing prospective randomized clinical trial, E2108, is addressing the role of surgery for the primary tumor in metastatic setting. </s> |
What is the role of tamoxifen and raloxifene for the reduction of breast cancer risk? |
Two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are approved for reduction of breast cancer risk in high-risk women. Two NSABP trials (P1 and P2) showed that tamoxifen reduced the risk of DCIS and invasive breast cancer by 30-50%. In the NSABP P2 prevention trial, raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer but was 30% less effective than tamoxifen in reducing the risk of DCIS. Tamoxifen and raloxifene are equally effective in reducing the risk of ER-positive breast cancer in postmenopausal women. Raloxifene is associated with lower rates of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen is. The evidence does not allow determination of whether either agent decreases mortality from breast cancer. | <s>[INST] What is the role of tamoxifen and raloxifene for the reduction of breast cancer risk? [/INST]
Two selective estrogen receptor modulators (SERMs), tamoxifen and raloxifene, are approved for reduction of breast cancer risk in high-risk women. Two NSABP trials (P1 and P2) showed that tamoxifen reduced the risk of DCIS and invasive breast cancer by 30-50%. In the NSABP P2 prevention trial, raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer but was 30% less effective than tamoxifen in reducing the risk of DCIS. Tamoxifen and raloxifene are equally effective in reducing the risk of ER-positive breast cancer in postmenopausal women. Raloxifene is associated with lower rates of thromboembolic disease, benign uterine conditions, and cataracts than tamoxifen is. The evidence does not allow determination of whether either agent decreases mortality from breast cancer. </s> |
What are the ASCO guidelines for the pharmacologic reduction of breast cancer risk? | ASCO guidelines on endocrine therapy to reduce breast cancer risk recommend the following :
1) In premenopausal women who are at least 35 years old and have completed childbearing, tamoxifen (20 mg/day for 5 years) remains the standard of care for risk reduction. Low-dose tamoxifen (5 mg/day) may be an alternative in women with intraepithelial neoplasia.
2) Anastrozole, exemestane, or raloxifene should not be prescribed for breast cancer risk reduction in premenopausal women.
3) In postmenopausal women, the choice of endocrine therapy includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day).
The ASCO guidelines delineate the risk thresholds for use of individual agents, along with the benefits and risks that clinician and patient should discuss when considering endocrine therapy for primary breast cancer prevention | <s>[INST] What are the ASCO guidelines for the pharmacologic reduction of breast cancer risk? [/INST] ASCO guidelines on endocrine therapy to reduce breast cancer risk recommend the following :
1) In premenopausal women who are at least 35 years old and have completed childbearing, tamoxifen (20 mg/day for 5 years) remains the standard of care for risk reduction. Low-dose tamoxifen (5 mg/day) may be an alternative in women with intraepithelial neoplasia.
2) Anastrozole, exemestane, or raloxifene should not be prescribed for breast cancer risk reduction in premenopausal women.
3) In postmenopausal women, the choice of endocrine therapy includes anastrozole (1 mg/day) in addition to exemestane (25 mg/day), raloxifene (60 mg/day), or tamoxifen (20 mg/day).
The ASCO guidelines delineate the risk thresholds for use of individual agents, along with the benefits and risks that clinician and patient should discuss when considering endocrine therapy for primary breast cancer prevention </s> |
What is the role of mastectomy in the prevention of breast cancer? | In retrospective studies with median follow-up periods of 13-14 years, bilateral risk-reduction mastectomy decreased the risk of developing breast cancer by at least 90% in women at moderate to high risk and in those with known BRCA1/2 mutations. In women with deleterious mutations in other genes that are associated with a 2-fold or greater risk for breast cancer but without a compelling family history of breast cancer, the value of risk-reducing mastectomy is unknown.
NOTE: Woman who are considering prophylactic mastectomy should meet with a range of specialists to discuss the risks and benefits of surgery, including its potential psychosocial effects, as well as the nonsurgical options for reducing risk of breast cancer.These may include a breast health specialist, medical social worker, or cancer clinical psychologist or psychiatrist. | <s>[INST] What is the role of mastectomy in the prevention of breast cancer? [/INST] In retrospective studies with median follow-up periods of 13-14 years, bilateral risk-reduction mastectomy decreased the risk of developing breast cancer by at least 90% in women at moderate to high risk and in those with known BRCA1/2 mutations. In women with deleterious mutations in other genes that are associated with a 2-fold or greater risk for breast cancer but without a compelling family history of breast cancer, the value of risk-reducing mastectomy is unknown.
NOTE: Woman who are considering prophylactic mastectomy should meet with a range of specialists to discuss the risks and benefits of surgery, including its potential psychosocial effects, as well as the nonsurgical options for reducing risk of breast cancer.These may include a breast health specialist, medical social worker, or cancer clinical psychologist or psychiatrist. </s> |
What are the ASBrS recommendations for contralateral prophylactic mastectomy (CPM) in the treatment of breast cancer? | A consensus statement from the American Society of Breast Surgeons (ASBrS) recommends that women with unilateral breast cancer who are at average risk should be discouraged from undergoing a contralateral prophylactic mastectomy (CPM), because most of those women, with the possible exception of BRCA carriers, will not obtain a survival benefit, and CPM doubles the risk of surgical complications. However, the ASBrS advises that the final decision whether or not to proceed with contralateral prophylactic mastectomy is a result of the balance between benefits and risks of CPM and patient preference. | <s>[INST] What are the ASBrS recommendations for contralateral prophylactic mastectomy (CPM) in the treatment of breast cancer? [/INST] A consensus statement from the American Society of Breast Surgeons (ASBrS) recommends that women with unilateral breast cancer who are at average risk should be discouraged from undergoing a contralateral prophylactic mastectomy (CPM), because most of those women, with the possible exception of BRCA carriers, will not obtain a survival benefit, and CPM doubles the risk of surgical complications. However, the ASBrS advises that the final decision whether or not to proceed with contralateral prophylactic mastectomy is a result of the balance between benefits and risks of CPM and patient preference. </s> |
What are the differences between the NCCN and ASCO guidelines for the long-term monitoring of breast cancer survivors? | Check out the table to know the difference between NCCN and ASCO guidelines : https://emedicine.medscape.com/article/1947145-treatment#d16 | <s>[INST] What are the differences between the NCCN and ASCO guidelines for the long-term monitoring of breast cancer survivors? [/INST] Check out the table to know the difference between NCCN and ASCO guidelines : https://emedicine.medscape.com/article/1947145-treatment#d16 </s> |
What are ASCO guidelines for monitoring bone density following the treatment for breast cancer? | Women aged ≥65 years
-----------------------------------------------------------------------
Woman aged 60-64 years with ≥1 of the following:
1. Family history of osteoporosis
2. Low body weight
3. Prior nontraumatic fracture
4. Other risk factors (eg, smoking, sedentary lifestyle)
-----------------------------------------------------------------------
Postmenopausal women on aromatase inhibitors
-----------------------------------------------------------------------
Premenopausal women who develop treatment related premature menopause
----------------------------------------------------------------------- | <s>[INST] What are ASCO guidelines for monitoring bone density following the treatment for breast cancer? [/INST] Women aged ≥65 years
-----------------------------------------------------------------------
Woman aged 60-64 years with ≥1 of the following:
1. Family history of osteoporosis
2. Low body weight
3. Prior nontraumatic fracture
4. Other risk factors (eg, smoking, sedentary lifestyle)
-----------------------------------------------------------------------
Postmenopausal women on aromatase inhibitors
-----------------------------------------------------------------------
Premenopausal women who develop treatment related premature menopause
----------------------------------------------------------------------- </s> |
What is the role of postoperative imaging in the long-term monitoring of breast cancer? | Women who have had surgery for breast cancer may still require breast cancer screening with mammography. If a woman had a total mastectomy, then the other breast requires yearly follow-up, because there is still a higher risk that cancer will develop in the remaining breast. If the woman had a subcutaneous mastectomy, partial mastectomy, or lumpectomy, then that breast itself requires follow-up mammography.
The first mammogram is best performed 6 months postoperatively to provide a baseline for the new postoperative and postirradiation changes. Thereafter, mammography may be performed every 6-12 months for screening and follow-up | <s>[INST] What is the role of postoperative imaging in the long-term monitoring of breast cancer? [/INST] Women who have had surgery for breast cancer may still require breast cancer screening with mammography. If a woman had a total mastectomy, then the other breast requires yearly follow-up, because there is still a higher risk that cancer will develop in the remaining breast. If the woman had a subcutaneous mastectomy, partial mastectomy, or lumpectomy, then that breast itself requires follow-up mammography.
The first mammogram is best performed 6 months postoperatively to provide a baseline for the new postoperative and postirradiation changes. Thereafter, mammography may be performed every 6-12 months for screening and follow-up </s> |
What is the role of postoperative imaging in the monitoring of metastatic breast cancer? | Recommendations for monitoring disease response in the metastatic setting vary. In general, monthly evaluations consisting of a history and physical examination to evaluate progression of disease and toxicities are reasonable.
Measurement of tumor markers, such as CEA, CA15.3, and CA27.29, can be used in conjunction with diagnostic imaging, history, and physical examination for monitoring patients on active therapy. CA15.3 and CA27.29 levels correlate with the course of disease in 60-70% of patients, whereas CEA levels correlate in 40% of patients.
However, data are insufficient to recommend the use of CEA, CA15.3, or CA27.29 alone for monitoring response to treatment. Caution should be used in the interpretation of rising CEA, CA15.3, or CA27.29 levels during the first 4-6 weeks of a new therapy; spurious early rises may occur. | <s>[INST] What is the role of postoperative imaging in the monitoring of metastatic breast cancer? [/INST] Recommendations for monitoring disease response in the metastatic setting vary. In general, monthly evaluations consisting of a history and physical examination to evaluate progression of disease and toxicities are reasonable.
Measurement of tumor markers, such as CEA, CA15.3, and CA27.29, can be used in conjunction with diagnostic imaging, history, and physical examination for monitoring patients on active therapy. CA15.3 and CA27.29 levels correlate with the course of disease in 60-70% of patients, whereas CEA levels correlate in 40% of patients.
However, data are insufficient to recommend the use of CEA, CA15.3, or CA27.29 alone for monitoring response to treatment. Caution should be used in the interpretation of rising CEA, CA15.3, or CA27.29 levels during the first 4-6 weeks of a new therapy; spurious early rises may occur. </s> |
How is radiation-induced heart disease monitored in patients with breast cancer? | According to a consensus statement from the European Association of Cardiovascular Imaging and the American Society of Echocardiography, patients treated with radiotherapy to the chest for Hodgkin's disease, or breast, lung, or esophageal cancer, should have an echocardiogram every 5 to 10 years to detect radiation-induced heart disease (RIHD). The relative risk of RIHD is 2- to 5.9 times higher in patients treated with radiation for breast cancer. | <s>[INST] How is radiation-induced heart disease monitored in patients with breast cancer? [/INST] According to a consensus statement from the European Association of Cardiovascular Imaging and the American Society of Echocardiography, patients treated with radiotherapy to the chest for Hodgkin's disease, or breast, lung, or esophageal cancer, should have an echocardiogram every 5 to 10 years to detect radiation-induced heart disease (RIHD). The relative risk of RIHD is 2- to 5.9 times higher in patients treated with radiation for breast cancer. </s> |
What are Society for Integrative Oncology guidelines for use of integrative therapy in breast cancer? | The Society for Integrative Oncology has released clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. Recommendations include the following :
1) Meditation, yoga, and relaxation with imagery may be useful for alleviating anxiety and mood disorders (grade A evidence)
2) Stress management, yoga, massage, music therapy, energy conservation, and meditation may reduce stress, improve mood, decrease fatigue, and improve quality of life (grade B evidence)
3) Acetyl-L-carnitine for the prevention of taxane-induced neuropathy may increase neuropathy and should not be used (grade H [likely harmful])
4) Evidence of benefit is weak or lacking for many interventions | <s>[INST] What are Society for Integrative Oncology guidelines for use of integrative therapy in breast cancer? [/INST] The Society for Integrative Oncology has released clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. Recommendations include the following :
1) Meditation, yoga, and relaxation with imagery may be useful for alleviating anxiety and mood disorders (grade A evidence)
2) Stress management, yoga, massage, music therapy, energy conservation, and meditation may reduce stress, improve mood, decrease fatigue, and improve quality of life (grade B evidence)
3) Acetyl-L-carnitine for the prevention of taxane-induced neuropathy may increase neuropathy and should not be used (grade H [likely harmful])
4) Evidence of benefit is weak or lacking for many interventions </s> |
Which organizations have issued guidelines on breast cancer screening? | Guidelines on breast cancer screening have been issued by the following organizations:
1) American Cancer Society (ACS)
2) U.S. Preventive Services Task Force (USPSTF)
3) American College of Obstetricians and Gynecologists (ACOG)
4) European Commission Initiative on Breast Cancer (ECIBC) | <s>[INST] Which organizations have issued guidelines on breast cancer screening? [/INST] Guidelines on breast cancer screening have been issued by the following organizations:
1) American Cancer Society (ACS)
2) U.S. Preventive Services Task Force (USPSTF)
3) American College of Obstetricians and Gynecologists (ACOG)
4) European Commission Initiative on Breast Cancer (ECIBC) </s> |
What are the ACS guidelines for breast self-exam (BSE)? | ACS recommendations for BSE are as follows :
1) Women should begin regular screening mammography at age 45 years (strong recommendation)
2) Women aged 45-54 years should be screened annually (qualified recommendation)
3) Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation)
4) Women should have the opportunity to begin annual screening at 40-44 years of age (qualified recommendation)
5) Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation) | <s>[INST] What are the ACS guidelines for breast self-exam (BSE)? [/INST] ACS recommendations for BSE are as follows :
1) Women should begin regular screening mammography at age 45 years (strong recommendation)
2) Women aged 45-54 years should be screened annually (qualified recommendation)
3) Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually (qualified recommendation)
4) Women should have the opportunity to begin annual screening at 40-44 years of age (qualified recommendation)
5) Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer (qualified recommendation) </s> |
What are ACS guidelines for the use of MRI in breast cancer screening? | The ACS considers a woman to be at average risk for breast cancer in the absence of all of the following:
A personal history of breast cancer
A strong family history of breast cancer
A genetic mutation known to increase risk of breast cancer (eg, in BRCA)
A history of chest radiation therapy before the age of 30
For average-risk women, the ACS screening recommendations are as follows:
Age 40-44 - Starting screening with annual mammography is an option.
Age 45-54 - Annual mammography is recommended.
Age 55 and older - Transition to biennial screening or have the opportunity to continue screening annually. Continue screening as long as the woman is in good health and has a life expectancy of at least 10 years.
Clinical breast exams are not recommended for breast cancer screening in average-risk women at any age. | <s>[INST] What are ACS guidelines for the use of MRI in breast cancer screening? [/INST] The ACS considers a woman to be at average risk for breast cancer in the absence of all of the following:
A personal history of breast cancer
A strong family history of breast cancer
A genetic mutation known to increase risk of breast cancer (eg, in BRCA)
A history of chest radiation therapy before the age of 30
For average-risk women, the ACS screening recommendations are as follows:
Age 40-44 - Starting screening with annual mammography is an option.
Age 45-54 - Annual mammography is recommended.
Age 55 and older - Transition to biennial screening or have the opportunity to continue screening annually. Continue screening as long as the woman is in good health and has a life expectancy of at least 10 years.
Clinical breast exams are not recommended for breast cancer screening in average-risk women at any age. </s> |
What are the USPSTF guidelines for breast self-exam (BSE)? | In 2016, the USPSTF released updated recommendations on breast cancer screening, but did not update its 2009 recommendations for breast examination. In its 2016 statement, the USPSTF encouraged patients to be aware of changes in their bodies and discussing these changes with clinicians.
The 2009 breast examination recommendations are as follows :
No requirement for clinicians to teach women how to perform BSE (Grade D recommendation)
Insufficient current evidence to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older | <s>[INST] What are the USPSTF guidelines for breast self-exam (BSE)? [/INST] In 2016, the USPSTF released updated recommendations on breast cancer screening, but did not update its 2009 recommendations for breast examination. In its 2016 statement, the USPSTF encouraged patients to be aware of changes in their bodies and discussing these changes with clinicians.
The 2009 breast examination recommendations are as follows :
No requirement for clinicians to teach women how to perform BSE (Grade D recommendation)
Insufficient current evidence to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older </s> |
What are the USPSTF guidelines for breast cancer screening? | Since 2009 the USPSTF has recommended biennial screening mammography for women aged 50-74 years (grade B recommendation). The USPSTF recommends against routine screening mammography in women aged 40-49 years because of high rates of false-negative findings, perceived harm of unnecessary biopsy, and concern for the harm associated with overdiagnosis and overtreatment (grade C recommendation). [97]
Instead of routine screening for women 40-49 years old, the USPSTF recommends that clinicians provide screening to selected patients in this age range, depending on individual circumstances and patient preferences. The USPSTF further concluded that for most individuals without signs or symptoms, there is likely to be only a small benefit from screening.
Finally, the USPSTF recommends against teaching breast self-examination and concludes that the current evidence is insufficient to assess the benefits and harms of clinical breast examination in women aged 40 years or older or the benefits and harms of screening mammography in women aged 75 years or older. | <s>[INST] What are the USPSTF guidelines for breast cancer screening? [/INST] Since 2009 the USPSTF has recommended biennial screening mammography for women aged 50-74 years (grade B recommendation). The USPSTF recommends against routine screening mammography in women aged 40-49 years because of high rates of false-negative findings, perceived harm of unnecessary biopsy, and concern for the harm associated with overdiagnosis and overtreatment (grade C recommendation). [97]
Instead of routine screening for women 40-49 years old, the USPSTF recommends that clinicians provide screening to selected patients in this age range, depending on individual circumstances and patient preferences. The USPSTF further concluded that for most individuals without signs or symptoms, there is likely to be only a small benefit from screening.
Finally, the USPSTF recommends against teaching breast self-examination and concludes that the current evidence is insufficient to assess the benefits and harms of clinical breast examination in women aged 40 years or older or the benefits and harms of screening mammography in women aged 75 years or older. </s> |
What are the USPSTF guidelines for BRCA-related breast cancer screening? | In 2013, the USPSTF issued updated guidelines on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. The current USPSTF recommendations are as follows:
Women who have family members with breast, ovarian, tubal, or peritoneal cancer should be screened to identify a family history that may be associated with an increased risk for mutations in the breast cancer susceptibility genes BRCA1 or BRCA2
Women who have positive screening results should receive genetic counseling and then BRCA testing if warranted
Women without a family history associated with an increased risk for mutations should not receive routine genetic counseling or BRCA testing | <s>[INST] What are the USPSTF guidelines for BRCA-related breast cancer screening? [/INST] In 2013, the USPSTF issued updated guidelines on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women. The current USPSTF recommendations are as follows:
Women who have family members with breast, ovarian, tubal, or peritoneal cancer should be screened to identify a family history that may be associated with an increased risk for mutations in the breast cancer susceptibility genes BRCA1 or BRCA2
Women who have positive screening results should receive genetic counseling and then BRCA testing if warranted
Women without a family history associated with an increased risk for mutations should not receive routine genetic counseling or BRCA testing </s> |
How are the ACOG guidelines for breast cancer screening categorized? | The ACOG released guidelines for breast cancer risk assessment and screening in average-risk women in 2017. [184] For women at average risk, ACOG categorizes its recommendations as follows:
Level A – Based on good and consistent scientific evidence
Level B – Based on limited or inconsistent scientific evidence
Level C – Based primarily on consensus and expert opinion
ACOG recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level B). Breast cancer risk factors include a long list. Visit the provided link for more information. | <s>[INST] How are the ACOG guidelines for breast cancer screening categorized? [/INST] The ACOG released guidelines for breast cancer risk assessment and screening in average-risk women in 2017. [184] For women at average risk, ACOG categorizes its recommendations as follows:
Level A – Based on good and consistent scientific evidence
Level B – Based on limited or inconsistent scientific evidence
Level C – Based primarily on consensus and expert opinion
ACOG recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level B). Breast cancer risk factors include a long list. Visit the provided link for more information. </s> |
According to ACOG guidelines, which breast cancer risk factors should be periodically assessed in women? | ACOG recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level B). Breast cancer risk factors include the following:
Family history of breast cancer, ovarian cancer, or other hereditary breast and ovatrians syndrome-associated cancer (eg, prostate cancer, pancreatic cancer)
Known deleterious gene mutation
Prior breast biopsy with atypical hyperplasia (lobular or ductal) or lobular carcinoma in situ
Early menarche
Late menopause
Nulliparity
Prolonged interval between menarche and first pregnancy
Menopausal hormone therapy with estrogen and progestin (decreased risk with progestin alone)
Not breastfeeding
Increasing age
Certain ethnicities (eg, higher likelihood of BRCA mutation in Ashkenazi Jewish women)
Higher body mass index
Alcohol consumption
Smoking
Dense breasts on mammography
Prior exposure to high-dose therapeutic chest irradiation at age 10-30 years | <s>[INST] According to ACOG guidelines, which breast cancer risk factors should be periodically assessed in women? [/INST] ACOG recommends that health care providers periodically assess patients' breast cancer risk by reviewing the history (level B). Breast cancer risk factors include the following:
Family history of breast cancer, ovarian cancer, or other hereditary breast and ovatrians syndrome-associated cancer (eg, prostate cancer, pancreatic cancer)
Known deleterious gene mutation
Prior breast biopsy with atypical hyperplasia (lobular or ductal) or lobular carcinoma in situ
Early menarche
Late menopause
Nulliparity
Prolonged interval between menarche and first pregnancy
Menopausal hormone therapy with estrogen and progestin (decreased risk with progestin alone)
Not breastfeeding
Increasing age
Certain ethnicities (eg, higher likelihood of BRCA mutation in Ashkenazi Jewish women)
Higher body mass index
Alcohol consumption
Smoking
Dense breasts on mammography
Prior exposure to high-dose therapeutic chest irradiation at age 10-30 years </s> |
What are the ACOG guidelines for clinical breast exam to screen for breast cancer? | Women should be counseled about breast self-awareness (ie, awareness of the normal appearance and feel of their breasts) and encouraged to notify their health care provider if they experience a change (level C). However, breast self-examination is not recommended (level B).
Clinical breast examination remains a recommended part of the evaluation of women who are at high risk or have symptoms. Screening clinical breast examination may be offered to asymptomatic, average-risk women on the following schedules, in the context of an informed, shared decision-making approach that recognizes the uncertainty of its benefits and the possibility of adverse consequences (level C):
For women aged 25–39 years, clinical breast examinations may be offered every 1–3 years.
For women aged 40 years and older, clinical breast examination may be offered annually | <s>[INST] What are the ACOG guidelines for clinical breast exam to screen for breast cancer? [/INST] Women should be counseled about breast self-awareness (ie, awareness of the normal appearance and feel of their breasts) and encouraged to notify their health care provider if they experience a change (level C). However, breast self-examination is not recommended (level B).
Clinical breast examination remains a recommended part of the evaluation of women who are at high risk or have symptoms. Screening clinical breast examination may be offered to asymptomatic, average-risk women on the following schedules, in the context of an informed, shared decision-making approach that recognizes the uncertainty of its benefits and the possibility of adverse consequences (level C):
For women aged 25–39 years, clinical breast examinations may be offered every 1–3 years.
For women aged 40 years and older, clinical breast examination may be offered annually </s> |
What are the ACOG recommendations for breast cancer screening mammography? | The decision about the age to begin mammography screening should be made through a shared decision-making process that includes information about the potential benefits and harms. Recommendations (level A) for average-risk women are as follows:
Screening mammography should be offered starting at age 40 years.
If patient desires, after counseling, initiate mammography at age 40-49 years.
Women should begin screening mammography by no later than age 50 years.
| <s>[INST] What are the ACOG recommendations for breast cancer screening mammography? [/INST] The decision about the age to begin mammography screening should be made through a shared decision-making process that includes information about the potential benefits and harms. Recommendations (level A) for average-risk women are as follows:
Screening mammography should be offered starting at age 40 years.
If patient desires, after counseling, initiate mammography at age 40-49 years.
Women should begin screening mammography by no later than age 50 years.
</s> |
What are European Commission Initiative on Breast Cancer (ECIBC) screening guidelines? | The European Commission Initiative on Breast Cancer (ECIBC) screening guidelines include the following recommendations for women age 40-74 years who are at average risk of breast cancer [185] :
Age 40-44: no screening
Age 45-49: screening every 2 or 3 years
Age 50-69: screening every 2 years
Age 70-74: screening every 3 years | <s>[INST] What are European Commission Initiative on Breast Cancer (ECIBC) screening guidelines? [/INST] The European Commission Initiative on Breast Cancer (ECIBC) screening guidelines include the following recommendations for women age 40-74 years who are at average risk of breast cancer [185] :
Age 40-44: no screening
Age 45-49: screening every 2 or 3 years
Age 50-69: screening every 2 years
Age 70-74: screening every 3 years </s> |
Which organizations have issued guidelines for pharmacologic intervention for breast cancer risk reduction? | Guidelines for pharmacologic intervention in women who are at increased risk for breast cancer, but do not have a personal history of breast cancer, have been issued by the American Society of Clinical Oncology (ASCO) and the U.S. Preventive Services Task Force (USPSTF). The guidelines differ in their classification of increased risk and in their inclusion of women with lobular carcinoma in situ (LCIS). | <s>[INST] Which organizations have issued guidelines for pharmacologic intervention for breast cancer risk reduction? [/INST] Guidelines for pharmacologic intervention in women who are at increased risk for breast cancer, but do not have a personal history of breast cancer, have been issued by the American Society of Clinical Oncology (ASCO) and the U.S. Preventive Services Task Force (USPSTF). The guidelines differ in their classification of increased risk and in their inclusion of women with lobular carcinoma in situ (LCIS). </s> |
What are the ASCO guidelines on pharmacologic interventions for breast cancer risk reduction? | ASCO guidelines recommend the following [186] :
For premenopausal or postmenopausal women with increased risk for breast cancer, offer tamoxifen (20 mg/day for 5 years) to reduce the risk of invasive ER-positive breast cancer
In postmenopausal women, raloxifene (60 mg/day for 5 years) may also be considered
Off-label use of exemestane (25 mg/day for 5 years) should be discussed as an alternative to reduce the risk in postmenopausal women
All three agents should be discussed (including risks and benefits) with women aged 35 years or older without a personal history of breast cancer who are at increased risk of developing invasive breast cancer | <s>[INST] What are the ASCO guidelines on pharmacologic interventions for breast cancer risk reduction? [/INST] ASCO guidelines recommend the following [186] :
For premenopausal or postmenopausal women with increased risk for breast cancer, offer tamoxifen (20 mg/day for 5 years) to reduce the risk of invasive ER-positive breast cancer
In postmenopausal women, raloxifene (60 mg/day for 5 years) may also be considered
Off-label use of exemestane (25 mg/day for 5 years) should be discussed as an alternative to reduce the risk in postmenopausal women
All three agents should be discussed (including risks and benefits) with women aged 35 years or older without a personal history of breast cancer who are at increased risk of developing invasive breast cancer </s> |
What are the ASCO recommendations for use of tamoxifen in breast cancer risk reduction? | ASCO guidelines recommend that use of tamoxifen, 20 mg per day orally for 5 years, should be discussed as an option to reduce the risk of invasive breast cancer (BC), specifically ER-positive BC, in women 35 years of age or older who are premenopausal or postmenopausal and have a 5-year projected absolute breast cancer risk ≥ 1.66% or with LCIS. Risk reduction benefit continues for at least 10 years.
ASCO guidelines advise that tamoxifen not be used in the following cases:
In women with a history of deep vein thrombosis, pulmonary embolus, stroke, or transient ischemic attack or during prolonged immobilization
In combination with hormone therapy
In women who are pregnant, may become pregnant, or are nursing mothers | <s>[INST] What are the ASCO recommendations for use of tamoxifen in breast cancer risk reduction? [/INST] ASCO guidelines recommend that use of tamoxifen, 20 mg per day orally for 5 years, should be discussed as an option to reduce the risk of invasive breast cancer (BC), specifically ER-positive BC, in women 35 years of age or older who are premenopausal or postmenopausal and have a 5-year projected absolute breast cancer risk ≥ 1.66% or with LCIS. Risk reduction benefit continues for at least 10 years.
ASCO guidelines advise that tamoxifen not be used in the following cases:
In women with a history of deep vein thrombosis, pulmonary embolus, stroke, or transient ischemic attack or during prolonged immobilization
In combination with hormone therapy
In women who are pregnant, may become pregnant, or are nursing mothers </s> |
What are the ASCO recommendations for use of raloxifene in breast cancer risk reduction? | ASCO guidelines recommend that raloxifene should be discussed as an option to reduce the risk of invasive BC, specifically ER-positive BC, in postmenopausal women who are age ≥ 35 years with a 5-year projected absolute BC risk ≥ 1.66% or with LCIS. Raloxifene is given in a dosage of 60 mg/ day orally for 5 years; it can be used for longer than 5 years in women with osteoporosis, in whom BC risk reduction is a secondary benefit.
ASCO guidelines advise that raloxifene not be used in the following cases:
For BC risk reduction in premenopausal women
In women with a history of deep vein thrombosis, pulmonary embolus, stroke, or transient ischemic attack or during prolonged immobilization | <s>[INST] What are the ASCO recommendations for use of raloxifene in breast cancer risk reduction? [/INST] ASCO guidelines recommend that raloxifene should be discussed as an option to reduce the risk of invasive BC, specifically ER-positive BC, in postmenopausal women who are age ≥ 35 years with a 5-year projected absolute BC risk ≥ 1.66% or with LCIS. Raloxifene is given in a dosage of 60 mg/ day orally for 5 years; it can be used for longer than 5 years in women with osteoporosis, in whom BC risk reduction is a secondary benefit.
ASCO guidelines advise that raloxifene not be used in the following cases:
For BC risk reduction in premenopausal women
In women with a history of deep vein thrombosis, pulmonary embolus, stroke, or transient ischemic attack or during prolonged immobilization </s> |
What are the ASCO recommendations for use of exemestane in breast cancer risk reduction? | Exemestane is not FDA approved for breast cancer risk reduction. However, ASCO guidelines recommend that it should be discussed as an alternative to tamoxifen and/or raloxifene to reduce the risk of invasive BC, specifically ER-positive BC, in postmenopausal women age ≥ 35 years with a 5-year projected absolute BC risk ≥ 1.66% or with LCIS or atypical hyperplasia. It should not be used for BC risk reduction in premenopausal women. Exemestane is given in a dosage of 25 mg per day orally for 5 years. | <s>[INST] What are the ASCO recommendations for use of exemestane in breast cancer risk reduction? [/INST] Exemestane is not FDA approved for breast cancer risk reduction. However, ASCO guidelines recommend that it should be discussed as an alternative to tamoxifen and/or raloxifene to reduce the risk of invasive BC, specifically ER-positive BC, in postmenopausal women age ≥ 35 years with a 5-year projected absolute BC risk ≥ 1.66% or with LCIS or atypical hyperplasia. It should not be used for BC risk reduction in premenopausal women. Exemestane is given in a dosage of 25 mg per day orally for 5 years. </s> |
What are the USPSTF guidelines on pharmacologic interventions for breast cancer risk reduction? | The USPSTF updated its guidelines for primary breast cancer risk reduction in 2019. [178] The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors. | <s>[INST] What are the USPSTF guidelines on pharmacologic interventions for breast cancer risk reduction? [/INST] The USPSTF updated its guidelines for primary breast cancer risk reduction in 2019. [178] The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors. </s> |
Which organizations have issued guidelines for sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) in the treatment of breast cancer? | Guidelines for sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) have been issued by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). | <s>[INST] Which organizations have issued guidelines for sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) in the treatment of breast cancer? [/INST] Guidelines for sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) have been issued by the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN). </s> |
What are the ASCO guidelines for the use of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer? | A 2016 update on SLNB for patients with operable early-stage breast cancer by ASCO advises that SLNB may be offered to the following patients:
Women with multicentric tumors
Women with DCIS who will be undergoing mastectomy
Women who previously underwent breast and/or axillary surgery
Women who received preoperative/neoadjuvant systemic therapy
According to the ASCO guidelines, SLNB should not be performed in patients with any of the following:
Large or locally advanced invasive breast cancer (tumor size T3/T4)
Inflammatory breast cancer
DCIS (when breast-conserving surgery is planned)
Pregnancy | <s>[INST] What are the ASCO guidelines for the use of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer? [/INST] A 2016 update on SLNB for patients with operable early-stage breast cancer by ASCO advises that SLNB may be offered to the following patients:
Women with multicentric tumors
Women with DCIS who will be undergoing mastectomy
Women who previously underwent breast and/or axillary surgery
Women who received preoperative/neoadjuvant systemic therapy
According to the ASCO guidelines, SLNB should not be performed in patients with any of the following:
Large or locally advanced invasive breast cancer (tumor size T3/T4)
Inflammatory breast cancer
DCIS (when breast-conserving surgery is planned)
Pregnancy </s> |
What are the ASCO guidelines for the use of axillary lymph node dissection (ALND) in the treatment of breast cancer? | A 2016 update on SLNB for patients with operable early-stage breast cancer by ASCO advises that SLNB may be offered to the following patients [188] :
Women with multicentric tumors
Women with DCIS who will be undergoing mastectomy
Women who previously underwent breast and/or axillary surgery
Women who received preoperative/neoadjuvant systemic therapy | <s>[INST] What are the ASCO guidelines for the use of axillary lymph node dissection (ALND) in the treatment of breast cancer? [/INST] A 2016 update on SLNB for patients with operable early-stage breast cancer by ASCO advises that SLNB may be offered to the following patients [188] :
Women with multicentric tumors
Women with DCIS who will be undergoing mastectomy
Women who previously underwent breast and/or axillary surgery
Women who received preoperative/neoadjuvant systemic therapy </s> |
What are the NCCN guidelines on the use of sentinel lymph node biopsy (SLNB) for the treatment of breast cancer? | The NCCN guidelines recommend that SLNB should be performed and is the preferred method of axillary lymph node staging if the patient is an appropriate candidate for SLNB. [72] Candidates include patients who are clinically node negative at the time of breast cancer diagnosis, with or without 1–2 suspicious nodes on imaging, and for whom no preoperative systemic therapy is planned.
If the sentinel lymph node is negative, no further axillary surgery is a category 1 recommendation. The NCCN recommends axillary dissection level I/II if the sentinel node is not identified or if the sentinel node is positive but the patient fails to meet all the following criteria:
T1 or T2 tumor
Only one or two positive sentinel lymph nodes
Breast-conserving surgery
Whole-breast radiation therapy planned
No preoperative chemotherapy | <s>[INST] What are the NCCN guidelines on the use of sentinel lymph node biopsy (SLNB) for the treatment of breast cancer? [/INST] The NCCN guidelines recommend that SLNB should be performed and is the preferred method of axillary lymph node staging if the patient is an appropriate candidate for SLNB. [72] Candidates include patients who are clinically node negative at the time of breast cancer diagnosis, with or without 1–2 suspicious nodes on imaging, and for whom no preoperative systemic therapy is planned.
If the sentinel lymph node is negative, no further axillary surgery is a category 1 recommendation. The NCCN recommends axillary dissection level I/II if the sentinel node is not identified or if the sentinel node is positive but the patient fails to meet all the following criteria:
T1 or T2 tumor
Only one or two positive sentinel lymph nodes
Breast-conserving surgery
Whole-breast radiation therapy planned
No preoperative chemotherapy </s> |
What are the NCCN guidelines for fine needle aspiration (FNA) and core biopsy in the treatment of breast cancer? | The NCCN recommends fine needle aspiration (FNA) or core biopsy for patients with any of the following characteristics:
Clinically node positive (3 or more positive nodes on physical exam and/or imaging) at time of diagnosis or
≥T2 or ≥N1 and with preoperative systemic therapy planned or
T2–4,N1–3,M0
If FNA or core biopsy results are negative, the NCCN recommends SLNB. For those with positive results, the NCCN recommends axillary dissection I/II, although SLNB may be considered in selected cases (eg, patients with clinically negative nodes after neoadjuvant therapy). | <s>[INST] What are the NCCN guidelines for fine needle aspiration (FNA) and core biopsy in the treatment of breast cancer? [/INST] The NCCN recommends fine needle aspiration (FNA) or core biopsy for patients with any of the following characteristics:
Clinically node positive (3 or more positive nodes on physical exam and/or imaging) at time of diagnosis or
≥T2 or ≥N1 and with preoperative systemic therapy planned or
T2–4,N1–3,M0
If FNA or core biopsy results are negative, the NCCN recommends SLNB. For those with positive results, the NCCN recommends axillary dissection I/II, although SLNB may be considered in selected cases (eg, patients with clinically negative nodes after neoadjuvant therapy). </s> |
What are the NCCN guidelines for use of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer during pregnancy? | In contrast with ASCO, the NCCN concluded that insufficient data exist on which to base recommendations regarding the use of SLNB in pregnant women. The NCCN advises that whether to use SLNB in pregnancy should be an individualized decision, but cites a review recommending that SLNB should not be offered to pregnant women under 30 weeks' gestation. If SLNB is used, the NCCN advises that isosulfan blue or methylene blue dye is discouraged for SLNB in pregnancy, and that the use of radioactive tracer (eg, technetium 99m sulfur colloid) is supported by limited data, with only case reports and estimations of fetal radiation dose. | <s>[INST] What are the NCCN guidelines for use of sentinel lymph node biopsy (SLNB) in the treatment of breast cancer during pregnancy? [/INST] In contrast with ASCO, the NCCN concluded that insufficient data exist on which to base recommendations regarding the use of SLNB in pregnant women. The NCCN advises that whether to use SLNB in pregnancy should be an individualized decision, but cites a review recommending that SLNB should not be offered to pregnant women under 30 weeks' gestation. If SLNB is used, the NCCN advises that isosulfan blue or methylene blue dye is discouraged for SLNB in pregnancy, and that the use of radioactive tracer (eg, technetium 99m sulfur colloid) is supported by limited data, with only case reports and estimations of fetal radiation dose. </s> |
What were the ASCO/CAP guidelines for hormone receptor testing in patients with breast cancer? | ER testing of invasive breast cancers by validated immunohistochemistry remains the standard for predicting which patients may benefit from endocrine therapy; no other assays are recommended for this purpose.
Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, data on the benefit of endocrine therapy for cancers with 1-10% of cells staining ER positive are limited. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.
A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. | <s>[INST] What were the ASCO/CAP guidelines for hormone receptor testing in patients with breast cancer? [/INST] ER testing of invasive breast cancers by validated immunohistochemistry remains the standard for predicting which patients may benefit from endocrine therapy; no other assays are recommended for this purpose.
Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, data on the benefit of endocrine therapy for cancers with 1-10% of cells staining ER positive are limited. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.
A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. </s> |
What are the guidelines for breast-conserving surgery with whole-breast radiation therapy (WBRT) in ductal carcinoma in situ (DCIS) breast cancer? | A positive margin is associated with a significant increase in ipsilateral breast tumor recurrence (IBTR); this increased risk is not nullified by the use of WBRT
Negative margins halve the risk of IBTR and a 2 mm margin minimizes the risk of IBTR compared with smaller negative margins.
More widely clear margins do not significantly decrease IBTR compared with 2 mm margins.
Negative margins < 2 mm alone are not an indication for mastectomy; clinical judgment should be used in determining the need for further surgery in patients with negative margins < 2 mm. | <s>[INST] What are the guidelines for breast-conserving surgery with whole-breast radiation therapy (WBRT) in ductal carcinoma in situ (DCIS) breast cancer? [/INST] A positive margin is associated with a significant increase in ipsilateral breast tumor recurrence (IBTR); this increased risk is not nullified by the use of WBRT
Negative margins halve the risk of IBTR and a 2 mm margin minimizes the risk of IBTR compared with smaller negative margins.
More widely clear margins do not significantly decrease IBTR compared with 2 mm margins.
Negative margins < 2 mm alone are not an indication for mastectomy; clinical judgment should be used in determining the need for further surgery in patients with negative margins < 2 mm. </s> |
What are the guidelines for breast-conserving surgery with whole-breast radiation therapy (WBRT) in stages I and II invasive breast cancer? | The following consensus guideline, released in 2014 by the Society of Surgical Oncology and the American Society for Radiation Oncology, addresses margins for breast-conserving surgery with whole-breast irradiation (WBI) in stages I and II invasive breast cancer:
Positive margins are associated with at least a two-fold increase in ipsilateral breast tumor recurrence (IBTR)
Negative margins optimize IBTR; this risk is not significantly lowered by wider margin widths
IBTR rates are reduced with the use of systemic therapy; in patients who do not receive adjuvant systemic therapy, margins wider than no ink on tumor are not needed
Biologic subtypes do not indicate the need for margins wider than no ink on tumor
Margin width should not determine the choice of WBI delivery technique, fractionation, and boost dose | <s>[INST] What are the guidelines for breast-conserving surgery with whole-breast radiation therapy (WBRT) in stages I and II invasive breast cancer? [/INST] The following consensus guideline, released in 2014 by the Society of Surgical Oncology and the American Society for Radiation Oncology, addresses margins for breast-conserving surgery with whole-breast irradiation (WBI) in stages I and II invasive breast cancer:
Positive margins are associated with at least a two-fold increase in ipsilateral breast tumor recurrence (IBTR)
Negative margins optimize IBTR; this risk is not significantly lowered by wider margin widths
IBTR rates are reduced with the use of systemic therapy; in patients who do not receive adjuvant systemic therapy, margins wider than no ink on tumor are not needed
Biologic subtypes do not indicate the need for margins wider than no ink on tumor
Margin width should not determine the choice of WBI delivery technique, fractionation, and boost dose </s> |
What are the ASCO guidelines for postmastectomy radiation therapy in the treatment of breast cancer? | Clinical practice guidelines developed by the American Society of Clinical Oncology (ASCO), recommend that postmastectomy radiation therapy be performed according to the following criteria :
Positive postmastectomy margins
Primary tumors >5 cm
Involvement of ≥4 lymph nodes
Patients with more than four positive lymph nodes should also undergo prophylactic nodal radiation therapy at doses of 45-50 Gy to the axillary and supraclavicular regions. For patients in whom ALND shows no node involvement, axillary radiation therapy is not recommended. | <s>[INST] What are the ASCO guidelines for postmastectomy radiation therapy in the treatment of breast cancer? [/INST] Clinical practice guidelines developed by the American Society of Clinical Oncology (ASCO), recommend that postmastectomy radiation therapy be performed according to the following criteria :
Positive postmastectomy margins
Primary tumors >5 cm
Involvement of ≥4 lymph nodes
Patients with more than four positive lymph nodes should also undergo prophylactic nodal radiation therapy at doses of 45-50 Gy to the axillary and supraclavicular regions. For patients in whom ALND shows no node involvement, axillary radiation therapy is not recommended. </s> |
What are the ASCO treatment guidelines for HER2-positive breast cancer? | HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.
The combination of trastuzumab, pertuzumab, and a taxane is recommended for first-line treatment.
Trastuzumab emtansine is recommended for second-line treatment.
In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. | <s>[INST] What are the ASCO treatment guidelines for HER2-positive breast cancer? [/INST] HER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis.
The combination of trastuzumab, pertuzumab, and a taxane is recommended for first-line treatment.
Trastuzumab emtansine is recommended for second-line treatment.
In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. </s> |
What are the ASCO guidelines for the use of hormonal adjuvant therapy in the treatment of premenopausal women with breast cancer? | SCO recommends high-risk women receive adjuvant endocrine therapy with ovarian suppression but lower-risk patients should not.
Women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy
Women with stage I or II breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy
Women with stage I breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression
Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression
Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor | <s>[INST] What are the ASCO guidelines for the use of hormonal adjuvant therapy in the treatment of premenopausal women with breast cancer? [/INST] SCO recommends high-risk women receive adjuvant endocrine therapy with ovarian suppression but lower-risk patients should not.
Women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy
Women with stage I or II breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy
Women with stage I breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression
Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression
Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor </s> |
What are the ASCO guidelines for adjuvant endocrine therapy in the treatment of postmenopausal women with breast cancer? | Women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy
Women with stage I or II breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy
Women with stage I breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression
Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression
Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor | <s>[INST] What are the ASCO guidelines for adjuvant endocrine therapy in the treatment of postmenopausal women with breast cancer? [/INST] Women with stage II or stage III breast cancers who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression in addition to endocrine therapy
Women with stage I or II breast cancers at higher risk of recurrence, who might consider chemotherapy, may also be offered ovarian suppression in addition to endocrine therapy
Women with stage I breast cancers not warranting chemotherapy should receive endocrine therapy but not receive ovarian suppression
Women with node-negative cancers 1 cm or less (T1a, T1b) should receive endocrine therapy but not receive ovarian suppression
Ovarian suppression may be administered with either tamoxifen or an aromatase inhibitor </s> |
What are guidelines on the treatment of breast cancer in young women? | There is no clear role for routine screening by any imaging technique for early breast cancer detection in healthy, average-risk young women. However, in young women with a cancer predisposition syndrome (germline mutation in a known cancer predisposition gene), significant family history, or prior personal history of ionizing radiation to the chest, consideration may be given to screening breast MRI.
In young women with the diagnosis of either invasive disease or preinvasive lesions who are not high-risk mutation carriers, there is no evidence that performing risk-reducing bilateral mastectomy leads to improved overall survival (OS). Visit the website for a lot more information. | <s>[INST] What are guidelines on the treatment of breast cancer in young women? [/INST] There is no clear role for routine screening by any imaging technique for early breast cancer detection in healthy, average-risk young women. However, in young women with a cancer predisposition syndrome (germline mutation in a known cancer predisposition gene), significant family history, or prior personal history of ionizing radiation to the chest, consideration may be given to screening breast MRI.
In young women with the diagnosis of either invasive disease or preinvasive lesions who are not high-risk mutation carriers, there is no evidence that performing risk-reducing bilateral mastectomy leads to improved overall survival (OS). Visit the website for a lot more information. </s> |
Which organizations issued guidelines on follow-up care for breast cancer survivors? | The National Comprehensive Cancer Network (NCCN) and the American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) have issued guidelines on followup care for breast cancer survivors. The guidelines differ principally in the timing of care. See the table in the website below. | <s>[INST] Which organizations issued guidelines on follow-up care for breast cancer survivors? [/INST] The National Comprehensive Cancer Network (NCCN) and the American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) have issued guidelines on followup care for breast cancer survivors. The guidelines differ principally in the timing of care. See the table in the website below. </s> |
What are ASCO guidelines for use of biomarkers in the treatment of breast cancer? | A guideline from the American Society of Clinical Oncology (ASCO) advises that the only biomarkers that can guide choices of specific treatment regimens in breast cancer are as follows:
Estrogen receptor (ER)
Progesterone receptor (PR)
Human epidermal growth factor receptor 2 (HER2) | <s>[INST] What are ASCO guidelines for use of biomarkers in the treatment of breast cancer? [/INST] A guideline from the American Society of Clinical Oncology (ASCO) advises that the only biomarkers that can guide choices of specific treatment regimens in breast cancer are as follows:
Estrogen receptor (ER)
Progesterone receptor (PR)
Human epidermal growth factor receptor 2 (HER2) </s> |
What are the NCCN guidelines for radical mastectomy in the treatment of breast cancer? | According to National Comprehensive Cancer Network (NCCN) guidelines, mastectomy with level I/II axillary lymph node dissection is the recommended procedure in patients who respond to neoadjuvant chemotherapy. Other NCCN indications include:
Prior radiation therapy to the breast or chest wall
Radiation therapy contraindicated by pregnancy (except patients in the third trimester who can receive radiation postpartum)
Inflammatory breast cancer
Diffuse suspicious or malignant-appearing microcalcifications
Widespread disease that is multicentric, located in more than one quadrant, and cannot be removed through a single incision with negative margins
A positive pathologic margin after repeat re-excision and suboptimal cosmetic outcome | <s>[INST] What are the NCCN guidelines for radical mastectomy in the treatment of breast cancer? [/INST] According to National Comprehensive Cancer Network (NCCN) guidelines, mastectomy with level I/II axillary lymph node dissection is the recommended procedure in patients who respond to neoadjuvant chemotherapy. Other NCCN indications include:
Prior radiation therapy to the breast or chest wall
Radiation therapy contraindicated by pregnancy (except patients in the third trimester who can receive radiation postpartum)
Inflammatory breast cancer
Diffuse suspicious or malignant-appearing microcalcifications
Widespread disease that is multicentric, located in more than one quadrant, and cannot be removed through a single incision with negative margins
A positive pathologic margin after repeat re-excision and suboptimal cosmetic outcome </s> |
What is the role of adjuvant therapies in the treatment of breast cancer? | Adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. It is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. | <s>[INST] What is the role of adjuvant therapies in the treatment of breast cancer? [/INST] Adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. It is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. </s> |
Which medications are used in the adjuvant treatment of breast cancer? | Medication Summary
Adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. It is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. | <s>[INST] Which medications are used in the adjuvant treatment of breast cancer? [/INST] Medication Summary
Adjuvant treatment for breast cancer involves radiation therapy and a variety of chemotherapeutic and biologic agents. It is designed to treat micrometastatic disease (or breast cancer cells that have escaped the breast and regional lymph nodes but which have not yet had an established identifiable metastasis). Treatment is aimed at reducing the risk of future recurrence, thereby reducing breast cancer−related morbidity and mortality.
In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. </s> |
Which medications in the drug class Antineoplastics, Estrogen Receptor Antagonist are used in the treatment of Breast Cancer? | Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis, had been approved for use in combination therapy for metastatic breast cancer. In November 2011, however, the US Food and Drug Administration (FDA) revoked its approval for this indication, after concluding that bevacizumab had not been shown to be safe and effective for that use. [72]
Anthracyclines work in multiple ways, including intercalation between DNA base pairs and inhibition of type II topoisomerase function, resulting in inhibition of cell replication and transcription. They also work by inhibition of DNA helicase, resulting in DNA cleavage. | <s>[INST] Which medications in the drug class Antineoplastics, Estrogen Receptor Antagonist are used in the treatment of Breast Cancer? [/INST] Bevacizumab, a humanized monoclonal antibody that inhibits angiogenesis, had been approved for use in combination therapy for metastatic breast cancer. In November 2011, however, the US Food and Drug Administration (FDA) revoked its approval for this indication, after concluding that bevacizumab had not been shown to be safe and effective for that use. [72]
Anthracyclines work in multiple ways, including intercalation between DNA base pairs and inhibition of type II topoisomerase function, resulting in inhibition of cell replication and transcription. They also work by inhibition of DNA helicase, resulting in DNA cleavage. </s> |
Which medications in the drug class Antineoplastics, PARP Inhibitors are used in the treatment of Breast Cancer? | This class of agents is thought to augment cytotoxic therapy without increasing side effects and to kill cancer cells with DNA repair defects as a single agent. The genomic instability of some tumor cells allows poly (ADP-ribose) polymerase (PARP) inhibitors to have selectivity for the tumor cells over normal cells.
Olaparib was the first PARP inhibitor approved for breast cancer. Its approval was based on the first phase 3 randomized trial that demonstrated PARP inhibitors were superior to chemotherapy for patients with HER2-negative metastatic breast cancer with a BRCA mutation. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, PARP Inhibitors are used in the treatment of Breast Cancer? [/INST] This class of agents is thought to augment cytotoxic therapy without increasing side effects and to kill cancer cells with DNA repair defects as a single agent. The genomic instability of some tumor cells allows poly (ADP-ribose) polymerase (PARP) inhibitors to have selectivity for the tumor cells over normal cells.
Olaparib was the first PARP inhibitor approved for breast cancer. Its approval was based on the first phase 3 randomized trial that demonstrated PARP inhibitors were superior to chemotherapy for patients with HER2-negative metastatic breast cancer with a BRCA mutation. See link for full list of medications. </s> |
Which medications in the drug class CDK Inhibitors are used in the treatment of Breast Cancer? | Palbociclib and ribociclib are cyclin-dependent kinases (CDK) 4, 6 inhibitors indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. See link for full list of medications. | <s>[INST] Which medications in the drug class CDK Inhibitors are used in the treatment of Breast Cancer? [/INST] Palbociclib and ribociclib are cyclin-dependent kinases (CDK) 4, 6 inhibitors indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. See link for full list of medications. </s> |
Which medications in the drug class Aromatase Inhibitors are used in the treatment of Breast Cancer? | In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. See link for full list of medications. | <s>[INST] Which medications in the drug class Aromatase Inhibitors are used in the treatment of Breast Cancer? [/INST] In patients receiving adjuvant aromatase inhibitor therapy for breast cancer who are at high risk for fracture, the monoclonal antibody denosumab or either of the bisphosphonates zoledronic acid and pamidronate may be added to the treatment regimen to increase bone mass. These agents are given along with calcium and vitamin D supplementation. See link for full list of medications. </s> |
Which medications in the drug class Antineoplastics, Antimicrotubular are used in the treatment of Breast Cancer? | Use of antimicrotubular therapy may be considered in patients who have received at least 2 chemotherapeutic regimens for metastatic disease. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, Antimicrotubular are used in the treatment of Breast Cancer? [/INST] Use of antimicrotubular therapy may be considered in patients who have received at least 2 chemotherapeutic regimens for metastatic disease. See link for full list of medications. </s> |
Which medications in the drug class Tyrosine Kinase Inhibitors are used in the treatment of Breast Cancer? | Tyrosine kinase inhibitors play an important role in the modulation of growth factor signaling. They are commonly combined with other forms of chemotherapy or radiation therapy. See link for full list of medications. | <s>[INST] Which medications in the drug class Tyrosine Kinase Inhibitors are used in the treatment of Breast Cancer? [/INST] Tyrosine kinase inhibitors play an important role in the modulation of growth factor signaling. They are commonly combined with other forms of chemotherapy or radiation therapy. See link for full list of medications. </s> |
Which medications in the drug class Monoclonal Antibodies are used in the treatment of Breast Cancer? | Monoclonal antibodies have been engineered to react against specific antigens on cancer cells, thereby potentially helping to enhance the patient’s immune response and prevent cancer cell growth. See link for full list of medications. | <s>[INST] Which medications in the drug class Monoclonal Antibodies are used in the treatment of Breast Cancer? [/INST] Monoclonal antibodies have been engineered to react against specific antigens on cancer cells, thereby potentially helping to enhance the patient’s immune response and prevent cancer cell growth. See link for full list of medications. </s> |
Which medications in the drug class Antineoplastics, Vinca Alkaloid are used in the treatment of Breast Cancer? | Antimetabolite therapy can stop cancer cell growth and cell division by interfering with DNA replication of these cells. These drugs are often first-line agents for breast cancer. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, Vinca Alkaloid are used in the treatment of Breast Cancer? [/INST] Antimetabolite therapy can stop cancer cell growth and cell division by interfering with DNA replication of these cells. These drugs are often first-line agents for breast cancer. See link for full list of medications. </s> |
Which medications in the drug class Antineoplastics, Antimetabolite are used in the treatment of Breast Cancer? | Antimetabolite therapy can stop cancer cell growth and cell division by interfering with DNA replication of these cells. These drugs are often first-line agents for breast cancer. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, Antimetabolite are used in the treatment of Breast Cancer? [/INST] Antimetabolite therapy can stop cancer cell growth and cell division by interfering with DNA replication of these cells. These drugs are often first-line agents for breast cancer. See link for full list of medications. </s> |
Which medications in the drug class Calcium Metabolism Modifiers are used in the treatment of Breast Cancer? | Bisphosphonates are complementary to chemotherapy and hormone therapy because they may lessen the damage to bone from metastatic disease. Bisphosphonates inhibit osteoclast function and reduce the resorption of bone. An intravenous bisphosphonate should be used in combination with oral calcium citrate and vitamin D supplementation in bone metastasis, according to the National Comprehensive Cancer Network (NCCN) guidelines. See link for full list of medications. | <s>[INST] Which medications in the drug class Calcium Metabolism Modifiers are used in the treatment of Breast Cancer? [/INST] Bisphosphonates are complementary to chemotherapy and hormone therapy because they may lessen the damage to bone from metastatic disease. Bisphosphonates inhibit osteoclast function and reduce the resorption of bone. An intravenous bisphosphonate should be used in combination with oral calcium citrate and vitamin D supplementation in bone metastasis, according to the National Comprehensive Cancer Network (NCCN) guidelines. See link for full list of medications. </s> |
Which medications in the drug class Antineoplastics, Anthracycline are used in the treatment of Breast Cancer? | Anthracyclines work in multiple ways, including intercalation between DNA base pairs and inhibition of type II topoisomerase function, resulting in inhibition of cell replication and transcription. They also work by inhibition of DNA helicase, resulting in DNA cleavage. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, Anthracycline are used in the treatment of Breast Cancer? [/INST] Anthracyclines work in multiple ways, including intercalation between DNA base pairs and inhibition of type II topoisomerase function, resulting in inhibition of cell replication and transcription. They also work by inhibition of DNA helicase, resulting in DNA cleavage. See link for full list of medications. </s> |
Which medications in the drug class Antineoplastics, Alkylating are used in the treatment of Breast Cancer? | Alkylating agents constitute one of the earliest classes of antineoplastic agents used to treat cancer. They work by cross-linking DNA, which impedes cellular growth. They can be used alone or in combination with other chemotherapeutic agents. See link for full list of medications. | <s>[INST] Which medications in the drug class Antineoplastics, Alkylating are used in the treatment of Breast Cancer? [/INST] Alkylating agents constitute one of the earliest classes of antineoplastic agents used to treat cancer. They work by cross-linking DNA, which impedes cellular growth. They can be used alone or in combination with other chemotherapeutic agents. See link for full list of medications. </s> |
Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Breast Cancer? | PD-L1 is expressed on the surface of activated T cells under normal conditions; binding PDL1 inhibits immune activation and reduces T-cell cytotoxic activity when bound. This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation. Tumor cells may circumvent T-cell–mediated cytotoxicity by expressing PDL1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells. See link for full list of medications. | <s>[INST] Which medications in the drug class PD-1/PD-L1 Inhibitors are used in the treatment of Breast Cancer? [/INST] PD-L1 is expressed on the surface of activated T cells under normal conditions; binding PDL1 inhibits immune activation and reduces T-cell cytotoxic activity when bound. This negative feedback loop is essential for maintaining normal immune responses and limits T-cell activity to protect normal cells during chronic inflammation. Tumor cells may circumvent T-cell–mediated cytotoxicity by expressing PDL1 on the tumor itself or on tumor-infiltrating immune cells, resulting in the inhibition of immune-mediated killing of tumor cells. See link for full list of medications. </s> |
Which medications in the drug class PI3K Inhibitors are used in the treatment of Breast Cancer? | PI3K inhibitor indicated in combination with fulvestrant for treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. | <s>[INST] Which medications in the drug class PI3K Inhibitors are used in the treatment of Breast Cancer? [/INST] PI3K inhibitor indicated in combination with fulvestrant for treatment of men and postmenopausal women with HR+/HER2- PIK3CA-mutated advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. </s> |
What are the risk factors for breast cancer? | Risk factors for breast cancer include age, family history of breast cancer, certain genetic mutations, hormone replacement therapy, alcohol consumption, obesity, and radiation exposure. | <s>[INST] What are the risk factors for breast cancer? [/INST] Risk factors for breast cancer include age, family history of breast cancer, certain genetic mutations, hormone replacement therapy, alcohol consumption, obesity, and radiation exposure. </s> |
How can I reduce my risk of breast cancer? | To reduce the risk of breast cancer, individuals can maintain a healthy weight, be physically active, limit alcohol intake, avoid smoking, breastfeed if possible, and undergo regular screenings. | <s>[INST] How can I reduce my risk of breast cancer? [/INST] To reduce the risk of breast cancer, individuals can maintain a healthy weight, be physically active, limit alcohol intake, avoid smoking, breastfeed if possible, and undergo regular screenings. </s> |
Is breast cancer hereditary? | While most cases of breast cancer are not hereditary, about 5-10% of breast cancers are linked to inherited genetic mutations, such as BRCA1 and BRCA2. Individuals with a family history of breast cancer may benefit from genetic counseling and testing. | <s>[INST] Is breast cancer hereditary? [/INST] While most cases of breast cancer are not hereditary, about 5-10% of breast cancers are linked to inherited genetic mutations, such as BRCA1 and BRCA2. Individuals with a family history of breast cancer may benefit from genetic counseling and testing. </s> |
What should I do if I find a lump in my breast? | If you find a lump or notice any other changes in your breast, it's essential to promptly consult a healthcare provider for evaluation. They may recommend further tests, such as a mammogram or biopsy, to determine the cause of the lump and develop an appropriate treatment plan. | <s>[INST] What should I do if I find a lump in my breast? [/INST] If you find a lump or notice any other changes in your breast, it's essential to promptly consult a healthcare provider for evaluation. They may recommend further tests, such as a mammogram or biopsy, to determine the cause of the lump and develop an appropriate treatment plan. </s> |
Can men get breast cancer? | Yes, although much less common than in women, men can develop breast cancer. It is estimated that about 1 in 833 men will be diagnosed with breast cancer in their lifetime. | <s>[INST] Can men get breast cancer? [/INST] Yes, although much less common than in women, men can develop breast cancer. It is estimated that about 1 in 833 men will be diagnosed with breast cancer in their lifetime. </s> |
Is breast cancer preventable? | While it's not always possible to prevent breast cancer, certain lifestyle choices and risk-reducing measures, such as maintaining a healthy weight, being physically active, and avoiding excessive alcohol consumption, can help lower the risk. | <s>[INST] Is breast cancer preventable? [/INST] While it's not always possible to prevent breast cancer, certain lifestyle choices and risk-reducing measures, such as maintaining a healthy weight, being physically active, and avoiding excessive alcohol consumption, can help lower the risk. </s> |
Can breast cancer spread to other parts of the body? | Yes, breast cancer can spread (metastasize) to other parts of the body, such as the bones, liver, lungs, or brain, if not detected and treated early. | <s>[INST] Can breast cancer spread to other parts of the body? [/INST] Yes, breast cancer can spread (metastasize) to other parts of the body, such as the bones, liver, lungs, or brain, if not detected and treated early. </s> |
What are the side effects of breast cancer treatment? | Side effects of breast cancer treatment may vary depending on the type of treatment but can include fatigue, nausea, hair loss, changes in appetite, menopausal symptoms, and emotional distress. | <s>[INST] What are the side effects of breast cancer treatment? [/INST] Side effects of breast cancer treatment may vary depending on the type of treatment but can include fatigue, nausea, hair loss, changes in appetite, menopausal symptoms, and emotional distress. </s> |
What support services are available for breast cancer patients? | Breast cancer patients have access to various support services, including counseling, support groups, financial assistance programs, and resources for managing treatment-related side effects and coping with the emotional impact of the disease. | <s>[INST] What support services are available for breast cancer patients? [/INST] Breast cancer patients have access to various support services, including counseling, support groups, financial assistance programs, and resources for managing treatment-related side effects and coping with the emotional impact of the disease. </s> |
Can breast cancer come back after treatment? | Yes, breast cancer can recur even after successful treatment. Regular follow-up appointments and monitoring are essential to detect any signs of recurrence early and adjust treatment as needed. | <s>[INST] Can breast cancer come back after treatment? [/INST] Yes, breast cancer can recur even after successful treatment. Regular follow-up appointments and monitoring are essential to detect any signs of recurrence early and adjust treatment as needed. </s> |
How can I support a loved one diagnosed with breast cancer? | Supporting a loved one with breast cancer involves offering emotional support, assisting with practical needs, accompanying them to medical appointments, and educating oneself about the disease and available resources. | <s>[INST] How can I support a loved one diagnosed with breast cancer? [/INST] Supporting a loved one with breast cancer involves offering emotional support, assisting with practical needs, accompanying them to medical appointments, and educating oneself about the disease and available resources. </s> |
What are the main types of medications used to treat breast cancer? | The main types of medications used to treat breast cancer include chemotherapy drugs, hormone therapy medications, targeted therapy drugs, and immunotherapy agents. | <s>[INST] What are the main types of medications used to treat breast cancer? [/INST] The main types of medications used to treat breast cancer include chemotherapy drugs, hormone therapy medications, targeted therapy drugs, and immunotherapy agents. </s> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.